Cambridge Healthtech Institute’s 3rd Annual

Small-Molecule Discovery Technologies

Innovations in Fragment-Based Drug Discovery and Emerging Lead-Generation Tools

April 20-21, 2027


CHI’s Small-Molecule Discovery Technologies conference covers lead-generation approaches ranging from well-established fragment-based ligand design to newer medicinal chemistry advances such as covalent chemistry and direct-to-biology (D2B) applications. A focus will also be on biophysical-based tools that enable small-molecule drug discovery against difficult-to-drug targets where detection of ligand-target interaction is the required readout because of the target's lack of enzymatic/functional activity. The companion Targeting Protein-Protein Interactions conference in the second half of Drug Discovery Chemistry delves deeper into promising compounds discovered as a result of innovations in Small-Molecule Discovery Technologies. The full event keeps you apprised of new approaches, innovative applications of well-established tools, and abreast of small-molecule compounds showing medical promise. All while providing the chance to interact with leaders in the fields of medicinal and biophysical chemistry.

Coverage will likely include:

  • Fragment-based drug discovery innovations, best-practices, and expanded applications
  • Covalent fragments as tools for TPD and induced-proximity discovery
  • Covalent inhibitor discovery
  • Direct-to-Biology (D2B) applications to lead generation
  • New methods related to, or uses of, biophysical tools (e.g., NMR, SPR, Mass Spectrometry, ASMS)
  • Merging information from various hit finding strategies (FBDD, DEL, Structure-Based Drug Design, Machine Learning) for more efficient hit-to-lead steps or drug candidate selection

The deadline for priority consideration is October 5, 2026.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:


For more details on the conference, please contact:
Anjani Shah, PhD
Senior Conference Director
Cambridge Healthtech Institute
(+1) 781-247-6252
Email: ashah@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners